STOCK TITAN
  1. Home
  2. Sec-filings
  3. TDOC
  4. [Form 4/A] Teladoc Health, Inc. Amended Insider Trading Activity

Teladoc (TDOC) executive earns 15,596 performance stock units tied to 2025 results

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4/A

Rhea-AI Filing Summary

Teladoc Health, Inc. President, U.S. Group Health, Kelly Bliss reported compensation-related equity activity involving performance stock units tied to common stock. On 2026-02-27, she was granted 15,596 performance stock units, each representing a contingent right to receive one share of TDOC common stock.

The award size was determined using metrics based on Teladoc’s 2025 financial results, and the units vest one-third on March 1, 2026, with the remainder vesting in eight substantially equal quarterly installments. The filing also records the exercise or conversion of 5,198 performance stock units into common stock and amends a prior Form 4 to correct the originally reported number of units awarded.

Positive

  • None.

Negative

  • None.
Insider Bliss Kelly
Role President, U.S. Group Health
Type Security Shares Price Value
Grant/Award Performance Stock Units 15,596 $0.00 $0.00
Exercise Performance Stock Units 5,198 $0.00 $0.00
Holdings After Transaction: Performance Stock Units — 10,398 shares (Direct)
Footnotes (6)
  1. F1. Each performance stock unit represents a contingent right to receive one share of TDOC common stock.
  2. F2. Performance award amount determined based on metrics in respect of the issuer's 2025 financial results.
  3. F3. The performance stock units vest as to one-third on March 1, 2026, with the remainder vesting in eight substantially equal quarterly installments thereafter.
  4. F4. The Form 4 filed March 3, 2026, inadvertently included an incorrect amount for the number of performance stock units awarded. This amendment reports the correct amount.
  5. F5. Performance stock units convert to shares of TDOC common stock on a one-for-one basis.
  6. F6. On March 1, 2026, the reporting person earned 15,596 performance stock units, vesting one-third on March 1, 2026, with the remainder vesting in eight substantially equal quarterly installments thereafter.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →

FAQ

What equity awards did Teladoc (TDOC) executive Kelly Bliss report in this Form 4/A?
Kelly Bliss reported a grant of 15,596 performance stock units, each exchangeable for one Teladoc common share. The filing also shows the exercise or conversion of 5,198 performance stock units into common stock as part of her compensation structure.

How are Kelly Bliss’s Teladoc (TDOC) performance stock units structured and vested?
Each performance stock unit equals one share of Teladoc common stock. One-third of the 15,596 units vests on March 1, 2026, with the remaining units vesting in eight substantially equal quarterly installments following that initial vesting date.

What performance period determines Kelly Bliss’s Teladoc (TDOC) PSU award size?
The number of performance stock units awarded to Kelly Bliss is determined based on metrics tied to Teladoc’s 2025 financial results. This means the company’s performance in 2025 directly influences the size of her 15,596-unit performance award.

What correction does this Teladoc (TDOC) Form 4/A make to the prior filing?
This amendment corrects an error in the Form 4 filed March 3, 2026, which included an incorrect number of performance stock units. The amended filing reports the accurate award amount of 15,596 performance stock units granted to Kelly Bliss.

When did Kelly Bliss earn the 15,596 Teladoc (TDOC) performance stock units?
Kelly Bliss earned 15,596 performance stock units on March 1, 2026. These units vest one-third on that date, with the remaining portion vesting through eight substantially equal quarterly installments over a subsequent multi-year period.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Bliss Kelly
(Last) (First) (Middle)
C/O TELADOC HEALTH, INC.,
155 E 44TH ST, SUITE 1700
(Street)
NEW YORK NY 10017
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Teladoc Health, Inc. [ TDOC ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
President, U.S. Group Health
3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
03/03/2026 		6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Performance Stock Units (1) 02/27/2026 A 15,596(2) (3) (3) Common Stock 15,596 $0 15,596(4) D
Performance Stock Units (5) 02/27/2026 M 5,198 (6) (6) Common Stock 5,198 $0 10,398(4) D
Explanation of Responses:
1. Each performance stock unit represents a contingent right to receive one share of TDOC common stock.
2. Performance award amount determined based on metrics in respect of the issuer's 2025 financial results.
3. The performance stock units vest as to one-third on March 1, 2026, with the remainder vesting in eight substantially equal quarterly installments thereafter.
4. The Form 4 filed March 3, 2026, inadvertently included an incorrect amount for the number of performance stock units awarded. This amendment reports the correct amount.
5. Performance stock units convert to shares of TDOC common stock on a one-for-one basis.
6. On March 1, 2026, the reporting person earned 15,596 performance stock units, vesting one-third on March 1, 2026, with the remainder vesting in eight substantially equal quarterly installments thereafter.
Remarks:
/s/ Adam C. Vandervoort, Attorney-in-Fact 03/12/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR